known shared risk factors for both CD and T1D. Nearly all patients with CD reveal either HLA-DQ2 (95%) or HLA-DQ8 (5%) upon HLA typing. 8, 9 Interestingly, HLA-DQ alleles are also mapped in nearly one-third of T1D cases. Overall, inheritance of certain HLA alleles has been well established to be associated with the risk of CD-T1D coexistence. Although the role of HLA loci has been extensively evaluated in risk association studies, there are few remarks on the impact of non-HLA genetic loci in determining the risk of CD and T1D co-development. In the present review, we have focused on a number of proposed shared non-HLA genetic loci and their possible interactions in determining the risk of either CD or T1D.
Search Strategy A comprehensive search was done on the Web of Knowledge, PubMed, and Scopus databases using keywords of polymorphism, coeliac disease, and type 1 diabetes. The star; "*" truncation was applied as "C*eliac" to recruit differentially spelled forms in Web of Knowledge and Scopus. Time spans included literature published within 2000-2017, and those assessed one of the shared genetic loci reported by Smyth et al. 10 Shared Non-HLA Loci Between CD and T1D Until recently, 42 non-HLA genes loci have been identified to modulate the risk and progression of the CD. 11 Among these, 7 shared loci have been proposed between CD and T1D so far (Table 1) . 10 In the following sections, we have discussed the potential role of these shared loci in determining the risk of CD and T1D development.
Cytotoxic T-Lymphocyte Associated Protein 4 Up to date, there have been about 100 polymorphic loci identified at the locus of cytotoxic T-lymphocyte associated protein 4 (CTL4) gene at chromosome 2q33. Some polymorphisms residing in CTLA4 locus (i.e. SNPs of CT60 G>A (rs3087243) and AG49 (rs231775)) have been correlated with lower levels of CTLA-4. The rs5742909 (-318 C/T) is another polymorphism located in the promoter region of CTLA-4 gene. Nevertheless, no significant impact was identified for this variant with neither CD 12 nor T1D. 27 The role of CT60 G>A (rs3087243) polymorphism has been noted in some autoimmune disorders. [40] [41] [42] [43] Reports of the impact of this polymorphism on protective or predisposing effects toward either CD and T1D have been conflicting. Smyth et al have considered a protective role for this polymorphism against both CD and T1D. 10 However, others have asserted a predisposing impact for this polymorphism for either CD 12 or T1D. [13] [14] [15] However, the susceptibility toward T1D has been noted for the wild-type allele at this locus. [13] [14] [15] Based on this, one can comprehend a parallel protective role for the minor allele (A) of this locus as noted in the study of Smyth et al. 10 Based on a proposed recessive mode for this polymorphism, general idea is that only homozygous wild-type combination of rs3087243 is associated with elevated risk for autoimmunity. 40 In fact, G allele of this polymorphism has been associated with depressed expression of CTLA-4. 44 Inheritance of rs231775 ( +49 A/G) polymorphism was shown to be linked to dampen levels of CLTA-4 in both plasma and cell surface of T lymphocytes. 45 These reduced levels, which subsequently lead to lower immunomodulatory effects of CTLA-4, have been accompanied with a higher rate of autoimmune conditions such as T1D, Graves disease, and graft rejection in transplanted individuals. 46, 47 Multiple studies have noted predisposing role for minor G allele of this polymorphism for CD 18 and T1D. [13] [14] [15] [19] [20] [21] [22] [23] [24] Two studies; Mora et al, Naluai et al 16, 17 have observed the higher risk of CD in individuals bearing the wild-type A allele of this polymorphism. On the other hand, some have not reported any significant association between this polymorphism with the occurrence of CD 12, 13 and T1D. 25, 26 Synergistic effects of CT60 G>A and +49 A/G polymorphisms of CTLA-4 gene has been noted as a dominant risk factor for the development of polyglandular autoimmunity (OR=4.89, 95% CI: 1.86-13.59). 40 Inheritance of two G alleles at the +49 locus within CTLA-4 gene result in a low functional index of CTLA-4. Nevertheless, individuals with homozygote signature for A allele may also develop autoimmune conditions indicating a multidisciplinary interaction for detraining risk of autoimmunity. 45 Actually, immune reactions are dependent on a complex interaction of non-HLA loci mediators with those of HLA II alleles. This is substantially important as HLA II molecules impart a significant role in antigen presentation to reactive T lymphocytes.
The function of T lymphocytes is negatively regulated by CTLA-4. Therefore, low activity of this molecule results in deregulated activation of T lymphocytes predisposing to autoimmune disorders. In fact, the use of immune checkpoint inhibitors (ICIs); ipilimumab (anti-CTLA-4), which has been proposed as an immunotherapy approach in malignancies, has been debated due to the possibility of an increased rate of autoimmune disorders. 48, 49 This molecule functionally belongs to immunoglobulin proteins and is highly detectable on the surface of T lymphocytes. In particular, CTLA-4 is identifiable in considerable copy numbers on the surface of regulatory T lymphocytes (CD4+CD25+FoxP3+) and also cytotoxic activated T cells. 50, 51 Recently, it has been proposed that regulatory T cells prevent autoimmune reactions through inhibition of dendritic cells (DCs) in a CTLA-4 dependent way. 52 CTLA-4 has been noted to counterbalance the signaling pathways originated form activator complexes on the surface of activated T lymphocytes namely CD28-B7. In fact, both CTLA-4 and CD28 are ligands for B7 family receptors on T lymphocyte membrane. However, CTLA-4 and CD28 competitivity bind and negatively and positively regulate T cell function respectively. 44, 53 Signaling pathways activated by the CTLA-4 was shown to induce tolerance against the development of autoimmune conditions. 54 In vitro blockage of CTLA-4/B7 complexes suppressed the proliferative activity of T lymphocytes in response to mitotic stimulators. The mechanisms for inhibitory effects of CTLA-4 are not fully understood, however, hindering from formation of CD28/B7 stimulatory complexes has been observed as a potential factor.
Regulator of G Protein Signaling
This molecule belongs to the family of regulator of G-protein signaling (RGS). The risk of some autoimmune disorders, including T1D, has been higher in carriers of polymorphism within RGS1 gene. The function of RGS1 is critical for recruitment of lymphocytic population into the lymphoid organ. This is achieved by modulation of chemokine receptor functions; CCR7 and CXCR4, by RGS1. [55] [56] [57] Through its potent GTPase activity, RGS1 suppresses signaling pathways originated form chemokine receptors. In fact, RGS1 degrades G-proteins which are mandatory downstream messengers for cellular signaling activities. 58 There are multiple reports indicating a significant protection against CD in individuals bearing the C allele of rs2816316 polymorphism mapped on RGS1 gene. [28] [29] [30] 33 In contrast, inheritance of this variant has been noted in association with a higher chance of being affected with T1D. 34 
SH2B Adaptor Protein
As for the genetic loci in the previous section, SH2B adaptor protein (SH2B3) also modulates signaling pathways derived from inflammatory cytokines and suppresses the proliferative activity of B and T lymphocytes. 59, 60 In particular, SH2B3 is a master regulator of the intracellular interaction of signaling adaptors participating in inflammatory reactions. 61 Due to the presence of conserved SH2 domain, these variant molecules of SH2B3 can inhibit formation and interaction of the NOD2 intracellular receptor and modulate ERK1/2 and p38MAPK pathways. 62 Importance of the rs3184504 polymorphism within SH2B3 is highlighted as carriers of the minor allele (T) at this locus are more prone to both CD 28, 35 and T1D. 10, 24, 36, 37 T Cell Activation Rho GTPase Activating Protein A single polymorphism (rs1738074), a variation mapped within the 5 -UTR region of the T cell activation Rho GTPase activating protein (TAGAP)gene, was noted to confer a protection against T1D. 10 Complementary to this, Romanos et al described an elevated risk of CD in individuals with minor (A) allele of this polymorphism. In contrast, Amundsen et al and Plaza-Izurieta et al stated no impacts regarding inheritance of this genetic variant with susceptibility to CD. 29, 30 Polymorphisms within TAGAP, located at 6q25, have been accompanied by various autoimmune diseases including CD. 63 As mentioned for RGS1, TAGAP also acts as an activator for GTPase functionality within cells. Nevertheless, TAGAP activates a specific GTPase unique for RhoA molecule which is merely expressed within activated T lymphocytes. 64, 65 Especially, TAGAP activation is critical in cytoskeleton rearrangements and migration of T lymphocytes. 66 Furthermore, TAGAP also binds RhoH; a molecule which interacts with Lck and ZAP70 molecules downstream to T cell receptor (TCR) cytoplasmic domain. Through this, TAGAP precludes ZAP70 from interacting with RhoH and suppresses TCR signaling. 64 Recently, TAGAP has been proposed as a potential target for induction of Th17 lymphocytes which are modulatory populations against autoimmune disorders.
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Interleukin 18 Receptor Accessory Protein Interleukin 18 receptor accessory protein (IL18RAP) is one component of heterodimeric IL-18R. The other subunit of this receptor is known as IL18R1. This complex is highly detectable on the surface of immune cells including T lymphocytes. During T cell activation and particularly in response to IL-12, IL-18RAP is activated and contributes to intracellular signaling pathways in lymphocytes. 67 Polymorphisms within the IL18RAP seem to exert antithetical roles in the development of CD and T1D. While rs2816316 (G minor allele) polymorphism was identified to protects against T1D, an elevated risk of CD has been described for carriers of rs917997 polymorphism. 29, 30 On the other hand, rs917997 polymorphism has been described as a protective factor against T1D while a risk factor for CD in another report. 68 The rs917997, a polymorphism located in the 3′ UTR, has been accompanied by depressed levels of IL18RAP in the serum of individuals with CD. 62, 69 Another polymorphism of this gene, rs13015714 was not found to exert a significant influence on the occurrence of CD. 30 Protein Tyrosine Phosphatase Non-receptor Type Smyth et al 10 have drawn conflicting conclusions regarding the role of 2 polymorphisms of this gene; rs478582 and rs45450798, regarding their protective and predisposing roles for CD respectively. In the same report, these researchers also found parallel effects of these polymorphisms regarding T1D (i.e. a protective role for rs478582 and a predisposing role for rs45450798). 10 Furthermore, Peng et al have noted lower odds for development of T1D in subjects with minor (G) allele of rs2542151 polymorphism of protein tyrosine phosphatase non-receptor type (PTPN2) gene. 31 In 2 additional reports, no significant association was reported between rs1893217 polymorphism of PTPN2 gene with T1D. 24, 32 The majority of polymorphic sites within PTPN2 reside with intronic regions. 70 These variants are supposed to give rise to alternative splicing sites resulting in altered stability of mRNA or non-sense frameshifts as well as epigenetic consequences, which all lead to altered bioavailability of the protein. 65 Both T1D and gastrointestinal disorders such as inflammatory bowel disease, Crohn disease as well as autoimmune disorders such as rheumatoid arthritis have been noted in association with polymorphisms within non-coding regions of PTPN2. [71] [72] [73] As for some of the previously mentioned loci, PTPN2 is also closely related to regulation of cytokine signaling.
74 PTPN2 belongs to a family of dephosphorylating enzymes breaking phosphates from tyrosine residues within the cytoplasmic domain of cytokine receptors. 75 Regarding functional activity, PTPN2 is particularly important in the regulation of T lymphocytes toward both self and foreign antigens. 76 Aberration of PTPN2 gene in animal models has been linked to higher susceptibility to autoimmune reactions in various organs such as kidney, skin, pancreas, and liver. 76 This observation has been accompanied by promoted activities of T and B lymphocytes as well as higher levels of proinflammatory cytokines. 76 C-C Motif Chemokine Receptor C-C motif chemokine receptor (CCR5) is involved in the recruitment of immune cells, including innate immunity cells such as T lymphocytes, to inflamed tissues. CCR5 is particularly bound to chemokine ligand 5, an attractant expressed by T lymphocytes, macrophage inflammatory protein-1, and monocyte chemoattractant protein-2. 77 A common genetic variant of CCR5, a 32 base pair deletion (rs333, 32-bp deletion), has been widely studied as a functional polymorphism within this gene. Homozygosity for this variant has been associated with dim expression of CCR5 on the cell membrane. 78 Smyth et al 10 and Słomiński et al 39 declared conflicting results regarding the impact of this polymorphic variant of CCR5 gene in the progression of CD (protective vs. predisposing respectively). In studies on T1D patients, however, multiple reports have stipulated a protective role for this polymorphism. 10, 38, 39, 79, 80 
Conclusion
Immune disorders are associated with aberrant regulation of immune functions. T1D and CD are two common forms of autoimmune diseases concomitantly observed in the considerable ratio of individuals. Although HLA loci play an important role in the determination of susceptibility to either CD and T1D, the role of shared non-HLA loci is less characterized. It seems that interaction of polymorphic variants of genes involved in regulation of immune cell activities, in particular T lymphocytes, with each other and with HLA loci to be critical in determining the risk of T1D and CD in the context of each other. Large population-based studies are warranted to explore the role of these loci in future studies.
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